In vivo CAR-T therapy using lentiviral vectors eliminates the need for ex vivo T-cell isolation and expansion. The core concept is the direct administration of a CAR-encoding lentiviral vector to the patient, in which a modified VSV-G envelope specifically recognizes and binds to T cells. The CAR transgene is then integrated into the T-cell genome, enabling CAR expression and the targeted elimination of tumor cells. This approach offers several notable advantages, including the elimination of complex ex vivo cell-manufacturing procedures, a significantly shorter production timeline, and broader patient accessibility, thereby expanding their applicability to the treatment of solid tumors.

● T cell-specific targeting via CD3 scFv 

● Reduced off-target transduction through fusogen detargeting

● Enhanced systemic stability via complement resistance